The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This RNS looks to be confirmation that the device can indeed detect Sepsis in blood sample. The timing of this update was projected in a previous update regarding the device. Very positive I would suggest.
I would say 2% increase in cost of debt would be £4m not £44m.
Does anyone have an idea when Q3 results will be published?
Please elaborate on your prediction!
Agreed that we have been hit by a “small” inflationary impact, but at this price I can’t see any issues in the medium term. We should also benefit b from the strength of the USD. They were confident enough to run the buyback scheme even during uncertainty.
Last annual results update.
“Approximately half of SEEIT's current portfolio by value has revenues that are partly or wholly inflation-linked, which culminates in an overall positive inflation correlation. Therefore, higher than expected inflation has had an overall small positive impact on the Company's returns during the year”
Complete and utter rubbish comment!
Do you have the right company!!!
does any more informed investors have any idea what happened to lsn software which was fda 510k approved and ce marked? i believe it was lsn rns releases that last sent the share price stratospheric!
also stonechecker? once to be sold, but kept in house, deemed to be more beneficial to the company. just a reminder, that these are still in the ****nal!
I note from
The announcement last year, that the Prostate trial was set to commence in Q3 2022 with a duration of 9 months. However I can’t find an RNS confirming when the trial actually commenced. Can anyone help?
Garry, I believe that it’s down to higher interest rates.
Investors may question: In principle, is the Divi premium % over a bank deposit % worth the risk?
When the debt has to be re-financed, the new rates will affect profit. However, their debt borrowing rate is currently low and fixed for a few years yet. A solid business model and discount to Nav, may well tempt longer term view investors.
Why haven’t they posted Nav values for some time now?
Nice to hear from for Izstar and hope that you are keeping well. It’s a shame that you lost out, but I guess that’s the risks and choices associated with share dealing! Hindsight is a wonderful thing, as I realise that I sold too soon, but of course the SP could have tanked a few days after the trial success, and I have been caught out before!
Anyway, thank you for your reply and best wishes for 2023.
It all came good in the end guys! Only 14 years for me and probably only made 20%, so allowing for inflation at 2% pa prior to 2021/23, I probably broke even. Sold out yesterday, a bit premature but happy to have finally got my money back.
I hope you guys managed to reap some benefit as well, after all this time.
Like you Thomson, I have held these for 14 years but sold out yesterday. Probably a bit premature based on today’s move. However, I have been badly burnt twice Renx and AGl, with both releasing excellent results. The former moving from $30 to $2 having been shorted to hell on the basis of no revenue.
Although very well funded, again VRNA now valued at $1.4b which again is massive based on potential!
No advice from me, but watch carefully if you intend to hold to revenue!
Very interesting take Tony.
All I would say is that, this needs to be resolved as soon as possible, which will likely still be at least a year or more. Then it will take some time to sort out and make safe before any assessment takes place, let alone mining. This is why the new new extensions and discoveries in the current areas, are very important stop gaps to development of new CA’s.
Good news out. Interesting to see how this goes on US open.